Adia Med Inc. (ADIA) Stock Price & Analysis
Adia Med Inc. (ADIA) — price $0.124 (0.00%), as of the Nov 19, 2026 trading session; market cap $11.7M.
Educational signal · not a buy or sell recommendation · How to read this
Adia Med Inc. · ADIA
Adia Nutrition, Inc. Despite its operational focus on health and wellness products, the company is officially classified within the Financial Services sector under the Shell Companies industry.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.124 | |
| Change on the day | 0.00% | |
| 52-week range | $0.0225 – $0.278 | |
| Market capitalisation | $11.7M | — |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for Adia Med (ADIA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Adia Med (ADIA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Adia Med Inc. (ADIA) is the company analyzed here. It employs 3 people and is led by Larry Powalisz. In Q2 FY2026 it reported revenue of $485,385 and net income of $40,418. The market values it at $11.7M.
What do the latest results show for Adia Med (ADIA)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $485,385.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $485,385 | $40,418 | $0.25 (diluted) |
| Q1 FY2026 | $176,275 | -$162,525 | -$1.72 (diluted) |
| Q4 FY2025 | $63,363 | -$219,358 | $0.00 (diluted) |
| Q3 FY2025 | $364,391 | $75,572 | $0.00 (diluted) |
What are the financial strengths and risks for Adia Med (ADIA)?
Short answer · as of
The distress and quality screens read Altman Z -4.31 · Piotroski F 3. Trailing ratios: ROE 94.3% · ROA -35.7% · current ratio 0.32 · free-cash-flow yield -1.4%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -4.31 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ADIA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ADIA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Adia Med (ADIA)?
- ADIA Med Nearly Doubles Nine-Month Revenue to Surpass $1 Million
- Adia Med CEO Larry Powalisz Issues Open Letter on Leadership Journey, Research Mission, and Progress Since 2024
- Adia Med Reports No Serious Adverse Events in First Cohort of Pediatric Autism Study; Enrollment Continues
- Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz for $350,000 in Cash
What Investors Ask About Adia Med (ADIA)
These answers are editorial: 2 of these 8 answers are drawn from the ADIA research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 6 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ADIA a good stock to buy?
Stock Expert AI does not rate ADIA buy, sell or hold. Adia Med Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ADIA stock price today?
The last price recorded for Adia Med Inc. (ADIA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is Adia Nutrition, Inc.'s primary business focus, given its classification as a Shell Company in the Financial Services sector?
Adia Nutrition, Inc. primarily operates in the health and wellness sector, specializing in the production and distribution of probiotic chews and drink mixes.
How does Adia Nutrition, Inc. generate revenue through its probiotic product offerings?
Adia Nutrition, Inc. generates revenue through the direct sale of its probiotic chews and drink mixes. The company employs a dual-channel distribution strategy to reach its customer base.
What are the key factors to evaluate for ADIA?
Evaluate ADIA on fundamentals, analyst consensus, and risk factors. The company does not offer a dividend yield, consistent with its current unprofitable financial performance and small operational scale. Not financial advice.
How frequently does ADIA data refresh on this page?
ADIA's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ADIA's recent stock price performance?
Adia Med Inc. (ADIA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio of probiotic chews and drink mixes catering to varied tastes and needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ADIA overvalued or undervalued right now?
Adia Med Inc. (ADIA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 7 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com